BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 24914134)

  • 1. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia.
    Cui B; Chen L; Zhang S; Mraz M; Fecteau JF; Yu J; Ghia EM; Zhang L; Bao L; Rassenti LZ; Messer K; Calin GA; Croce CM; Kipps TJ
    Blood; 2014 Jul; 124(4):546-54. PubMed ID: 24914134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.
    Sharma S; Pavlasova GM; Seda V; Cerna KA; Vojackova E; Filip D; Ondrisova L; Sandova V; Kostalova L; Zeni PF; Borsky M; Oppelt J; Liskova K; Kren L; Janikova A; Pospisilova S; Fernandes SM; Shehata M; Rassenti LZ; Jaeger U; Doubek M; Davids MS; Brown JR; Mayer J; Kipps TJ; Mraz M
    Blood; 2021 May; 137(18):2481-2494. PubMed ID: 33171493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the mRNA expression profile of B-cell receptor components in normal CD5-high B-lymphocytes and chronic lymphocytic leukemia: a key role of ZAP70.
    Gladkikh AA; Potashnikova DM; Tatarskiy V; Yastrebova M; Khamidullina A; Barteneva N; Vorobjev I
    Cancer Med; 2017 Dec; 6(12):2984-2997. PubMed ID: 29125235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL.
    Vasyutina E; Boucas JM; Bloehdorn J; Aszyk C; Crispatzu G; Stiefelhagen M; Breuer A; Mayer P; Lengerke C; Döhner H; Beutner D; Rosenwald A; Stilgenbauer S; Hallek M; Benner A; Herling M
    Leukemia; 2015 Oct; 29(10):2003-14. PubMed ID: 25936528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The miR-17∼92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes.
    Bomben R; Gobessi S; Dal Bo M; Volinia S; Marconi D; Tissino E; Benedetti D; Zucchetto A; Rossi D; Gaidano G; Del Poeta G; Laurenti L; Efremov DG; Gattei V
    Leukemia; 2012 Jul; 26(7):1584-93. PubMed ID: 22343732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1.
    Mraz M; Chen L; Rassenti LZ; Ghia EM; Li H; Jepsen K; Smith EN; Messer K; Frazer KA; Kipps TJ
    Blood; 2014 Jul; 124(1):84-95. PubMed ID: 24787006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.
    Cerna K; Oppelt J; Chochola V; Musilova K; Seda V; Pavlasova G; Radova L; Arigoni M; Calogero RA; Benes V; Trbusek M; Brychtova Y; Doubek M; Mayer J; Pospisilova S; Mraz M
    Leukemia; 2019 Feb; 33(2):403-414. PubMed ID: 30111844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression.
    Santanam U; Zanesi N; Efanov A; Costinean S; Palamarchuk A; Hagan JP; Volinia S; Alder H; Rassenti L; Kipps T; Croce CM; Pekarsky Y
    Proc Natl Acad Sci U S A; 2010 Jul; 107(27):12210-5. PubMed ID: 20566844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Karyotype-specific microRNA signature in chronic lymphocytic leukemia.
    Visone R; Rassenti LZ; Veronese A; Taccioli C; Costinean S; Aguda BD; Volinia S; Ferracin M; Palatini J; Balatti V; Alder H; Negrini M; Kipps TJ; Croce CM
    Blood; 2009 Oct; 114(18):3872-9. PubMed ID: 19717645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling.
    Yeh YY; Ozer HG; Lehman AM; Maddocks K; Yu L; Johnson AJ; Byrd JC
    Blood; 2015 May; 125(21):3297-305. PubMed ID: 25833959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia.
    Mraz M; Kipps TJ
    Leuk Lymphoma; 2013 Aug; 54(8):1836-9. PubMed ID: 23597135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.
    Chen L; Widhopf G; Huynh L; Rassenti L; Rai KR; Weiss A; Kipps TJ
    Blood; 2002 Dec; 100(13):4609-14. PubMed ID: 12393534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling.
    Dielschneider RF; Xiao W; Yoon JY; Noh E; Banerji V; Li H; Marshall AJ; Johnston JB; Gibson SB
    Cell Death Dis; 2014 Oct; 5(10):e1439. PubMed ID: 25275600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
    Motiwala T; Kutay H; Zanesi N; Frissora FW; Mo X; Muthusamy N; Jacob ST
    Leukemia; 2015 Jun; 29(6):1350-9. PubMed ID: 25482129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells.
    Calissano C; Damle RN; Marsilio S; Yan XJ; Yancopoulos S; Hayes G; Emson C; Murphy EJ; Hellerstein MK; Sison C; Kaufman MS; Kolitz JE; Allen SL; Rai KR; Ivanovic I; Dozmorov IM; Roa S; Scharff MD; Li W; Chiorazzi N
    Mol Med; 2011; 17(11-12):1374-82. PubMed ID: 21968788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The gene expression response of chronic lymphocytic leukemia cells to IL-4 is specific, depends on ZAP-70 status and is differentially affected by an NFκB inhibitor.
    Ruiz-Lafuente N; Alcaraz-García MJ; Sebastián-Ruiz S; Gómez-Espuch J; Funes C; Moraleda JM; García-Garay MC; Montes-Barqueros N; Minguela A; Álvarez-López MR; Parrado A
    PLoS One; 2014; 9(10):e109533. PubMed ID: 25280001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
    Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL.
    Nichols EM; Jones R; Watson R; Pepper CJ; Fegan C; Marchbank KJ
    Oncotarget; 2015 Oct; 6(32):32669-80. PubMed ID: 26452134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and function of the TL1A/DR3 axis in chronic lymphocytic leukemia.
    Cavallini C; Lovato O; Bertolaso A; Zoratti E; Malpeli G; Mimiola E; Tinelli M; Aprili F; Tecchio C; Perbellini O; Scarpa A; Zamò A; Cassatella MA; Pizzolo G; Scupoli MT
    Oncotarget; 2015 Oct; 6(31):32061-74. PubMed ID: 26393680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adhesion of ZAP-70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and blocked by inhibitors of the PI3-kinase pathway.
    Lafarge ST; Johnston JB; Gibson SB; Marshall AJ
    Leuk Res; 2014 Jan; 38(1):109-15. PubMed ID: 23981382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.